• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Beam Therapeutics Inc (NQ: BEAM )

    22.93 +1.02 (+4.66%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Beam Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
    From Beam Therapeutics
    Via GlobeNewswire
    Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
    Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
    Via Investor's Business Daily
    Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings)
    Via Benzinga
    A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
    Via Benzinga
    Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
    William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... 
    Via Benzinga
    3 Gene Editing Stocks with Potential to Transform Medicine
    Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. 
    Via InvestorPlace
    BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024
    BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
    From Beam Therapeutics
    Via GlobeNewswire
    ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
    Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
    Via Benzinga
    IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Beam Therapeutics Stock Earns RS Rating Jump To 85
    On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
    Via Investor's Business Daily
    Why Is Conn’s (CONN) Stock Down 36% Today?
    Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing. 
    Via InvestorPlace
    Topics Bankruptcy
    Exposures Financial Legal
    Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
    Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock. 
    Via InvestorPlace
    Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    3 Gene Editing Stocks Shaping the Future of Medicine
    Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions 
    Via InvestorPlace
    Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
    Via Benzinga
    Beam Therapeutics Announces Transition of Chief Financial Officer
    From Beam Therapeutics
    Via GlobeNewswire
    The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
    Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
    Via InvestorPlace
    3 Stocks With the Potential to 10X Your Money
    These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost. 
    Via InvestorPlace
    FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
    Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
    Via InvestorPlace
    Exposures Product Safety
    3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
    These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet. 
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
    The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects. 
    Via InvestorPlace
    Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
    From Beam Therapeutics
    Via GlobeNewswire
    Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
    These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
    Via InvestorPlace
    Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
    From Beam Therapeutics
    Via GlobeNewswire
    BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
    BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
    From Beam Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.